Adocia ACTAdocia ACTAdocia ACT

Adocia ACT

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪144.30 M‬USD
−0.613200USD
‪−10.08 M‬USD
‪10.08 M‬USD
Beta (1Y)
1.16

About Adocia ACT


CEO
Olivier Soula
Website
Headquarters
Lyon
Founded
2006
IPO date
Feb 20, 2012
Identifiers
3
ISIN US00725J1025
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: Biochaperone Lispro, Combo, M1pram, Glucagon, Gla Glp-1, Glucagon Glp-1 & Cell Therapy. The company was founded by Gérard Soula, Olivier Soula and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.

Check out other big names from the same industry as ADOCY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.